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Gellan gum is a polysaccharide that we have previously proposed for applications in the cartilage tissue
engineering field. In this work, gellan gum hydrogels were tested for their ability to be used as injectable systems
using simple processing methods, able to deliver and maintain chondrocytes by in situ gelation, and support cell
viability and production of extracellular matrix (ECM). Rheological measurements determined that the sol–gel
transition occurred near the body temperature at 398C, upon temperature decrease, in approximately 20 s. Gellan
gum discs shows a storage compression modulus of around 80 kPa at a frequency of 1Hz by dynamic me-
chanical analysis. Human articular chondrocytes were encapsulated in the gels, cultured in vitro for total periods
of 56 days, and analyzed for cell viability and ECM production. Calcein AM staining showed that cell kept viable
after 14 days and the histological analysis and real-time quantitative polymerase chain reaction revealed that
hyaline-like cartilage ECM was synthesized. Finally, the in vivo performance of the gellan gum hydrogels, in
terms of induced inflammatory reaction and integration into the host tissue, was evaluated by subcutaneous
implantation in Balb=c mice for 21 days. Histological analysis showed a residual fibrotic capsule at the end of the
experiments. Dynamic mechanical analysis revealed that the gels were stable throughout the experiments while
evidencing a tendency for decreasing mechanical properties, which was consistent with weight measurements.
Altogether, the results demonstrate the adequacy of gellan gum hydrogels processed by simple methods for
noninvasive injectable applications toward the formation of a functional cartilage tissue-engineered construct
and originally report the preliminary response of a living organism to the subcutaneous implantation of the
gellan gum hydrogels. These are the two novel features of this work.
Introduction
Cartilage is a tissue with relatively low or no turnover,both at cellular and molecular level, which leads to
difficulties in its repair and regeneration once traumatized.
The extracellular matrix (ECM) that is responsible for the
functionality of the tissue has to be maintained by scarcely
distributed chondrocytes, demanding a great anabolic ca-
pacity of these cells. Various therapeutic approaches that
have no active biologics were involved, such as arthroscopy,
debridement, laser abrasion, drilling, and microfracture.1–3
They involve mostly mechanical techniques that remove the
affected tissue and seek to stimulate the formation of healthy
tissue. Since the outcomes of these interventions are fre-
quently not satisfactory, namely in terms of functional tissue
recovery, alternative solutions for these problems are being
explored.1,4,5 Brittberg et al.6 performed autologous chon-
drocyte transplantation in 1994 by injecting expanded
chondrocytes into cartilage defects subsequently covered
with a sutured periosteal flap. Although the results were
successful in some cases, the percentage of failure led the
researchers to pursue other lines of study, including the use
of biomaterials and cells combined with bioactive agents in
tissue engineering strategies. Several biomaterials, from ei-
ther natural or synthetic origin, or combinations of both
types, have been proposed as supports for cell development
and tissue formation in cartilage tissue engineering. These
include alginate, hyaluronic acid, collagen, fibrin, chitosan,
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polyglycolic acid, or polyethylene oxide.7–10 Not only the
type of material is important for the overall performance of
the constructs but also its processing methodologies and the
application routes employed. Hydrogels, and especially
in situ injectable systems, have been gaining a wider interest
for cartilage regeneration applications.11–15 They can be used
in a minimally invasive manner by injecting into the defect
area, normally involve nonharsh methods and reagents,
possess the ability to adopt the shape of the defect thereby
facilitating integration, and may be optimized for sol–gel
transition to occur near body temperature while encapsu-
lating cells and=or bioactive agents of interest.
Gellan gum is a new biomaterial recently proposed for
tissue engineering applications,16 namely for cartilage re-
generation.17,18 In addition to the above mentioned advan-
tages of other injectable systems, gellan gum possess other
features that may place it as a potential candidate for the
clinical regeneration of cartilaginous tissues. Gellan gum is a
linear anionic polysaccharide composed of repeating units of
glucose, glucuronic acid, and rhamnose.19,20 It exists in the
acetylated form, which is the initial raw material, and the
deacetylated form, which is the most commonly used.21,22
Both form thermoreversible gels with differences in me-
chanical properties from soft and elastic for the acetylated
form, to hard and brittle for the fully deacetylated polysac-
charide which opens interesting prospects for the generation
of multifunctional structures.22,23 Gellan gum is noncytotoxic
and can be easily processed without the use of harsh re-
agents into transparent gels that are resistant to heat and acid
stress.24,25 Its gelation is ionotropic as in other polysaccha-
rides, like alginate or carrageenan, and therefore the presence
of cations is necessary for the formation of a stable hydrogel
structure. Upon temperature decrease of a gellan gum solu-
tion, the transition of a thermally reversible coil to a double-
helix chain occurs and is followed by a self-assembling
mechanism that forms oriented bundles. These link them-
selves through untwined polysaccharide chain regions cul-
minating in the formation of a stable gel.26 The quantity and
chemical nature of cations present in solution greatly affects
gellan gum gelation; divalent cations promote a more effi-
cient gelation than monovalent cations.26–28 Gellan gum gels
are commonly used in the food industry as thickening agents
or stabilizers.29 In the biomedical field, most applications are
suggested for drug delivery approaches.30–32 Its use in car-
tilage tissue engineering was pioneered by our group, and
the application for other soft tissues is currently under study.
In this work, gellan gum hydrogels were used as encap-
sulation agents and tissue engineering supports for human
articular chondrocytes. Gellan gum properties were opti-
mized and characterized so that they could be used as in-
jectable systems in minimally invasive procedures using
simple processing methodologies, being this one innovative
feature of this work. Gellan gum with encapsulated human
articular chondrocytes systems were tested in vitro for peri-
ods of up to 56 days of culture. Cell viability and ECM
formation and deposition were evaluated by molecular and
histological techniques. A preliminary in vivo evaluation
of the gellan gum hydrogels was also performed upon
subcutaneous implantation in Balb=c mice for total periods
of up to 21 days. The obtained results showed the suitability
of gellan gum hydrogels for injectable applications and in situ
cell delivery, suggesting a potential application in the future




Cone-plate rheometry was conducted for gellan gum hy-
drogels to assess their rheological behavior as function of
temperature and time. For this purpose, gellan gum (G1910;
Sigma-Aldrich, St. Louis, MO) powder was mixed at room
temperature with distilled water at a concentration of 1%
(w=v) under constant stirring. The solution was heated to
908C and kept at this temperature for 30min. Afterward,
CaCl2 was added to the gellan gum solution at a concen-
tration of 0.03% (w=v), and rheological measurements were
performed using a controlled stress cone-plate rheometer
(Reometer Reologica; StressTech, Lund, Sweden). For each
measurement, a volume of 2mL of the gellan gum solution
was placed in the bottom plate of the rheometer and kept at a
constant temperature of 708C. The polymer solution was
allowed to stabilize for 1min before starting the experiments.
Measurements were performed by decreasing the tempera-
ture from 708C to 258C (at a cooling rate of 68C=min) and
applying a constant shear stress of 0.1 Pa. Temperature, time,
shear rate, and viscosity were constantly measured. The total
number of repeats was five (n¼ 5), and confidence intervals
were estimated with a confidence level of 99%.
Dynamic mechanical analysis
Dynamic mechanical analysis (DMA) was conducted to
characterize the mechanical behavior of gellan gum hydrogel
discs. The samples were prepared using a methodology
previously described elsewhere.25 Gellan gum 1% (w=v)
discs (Ø 6 0.015.5 0.46mm height) were subjected to
compression cycles of increasing frequencies ranging from 0.1
to 10Hz with constant amplitude displacements of 0.1mm
using a Tritec 2000 DMA (Triton Technology, Nottingham-
shire, United Kingdom). Storage and loss modulus were
measured, and experiments were conducted at room tem-
perature. The total number of discs per assay were five
(n¼ 5). The described values for the compression modulus
were collected at a frequency of 1Hz. Statistical analysis was
performed using confidence intervals based on the experi-
mental results, with a confidence level of 99%.
Human articular chondrocytes isolation and expansion
Human articular cartilage was harvested from the femoral
head and condyles of adult patients (40–65 years) undergo-
ing knee arthroplasty surgery. This was performed within
the scope of a protocol established with the Hospital de S.
Marcos, Braga, Portugal, approved by its Ethical Committee
and upon patient informed consent. Chondrocytes were
isolated by enzymatic digestion; in detail, the human artic-
ular cartilage, free from all surrounding tissue, was placed in
a Petri dish containing sterile phosphate-buffered saline
(PBS) and cut into square slices of 5mm and thickness be-
tween 2 and 3mm. The pieces were washed in sterile PBS,
immersed in 20mL of trypsin–ethylenediaminetetraacetic
acid solution, and incubated for 30min at 378C under agi-
tation. Trypsin was removed and the tissue pieces washed
with basic Dulbecco’s modified Eagle’s medium (Sigma-
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Aldrich). Then 20mL of sterile collagenase type II solution
(2mg=mL) (Sigma-Aldrich) in basic medium was added, and
the mixture was incubated for approximately 12 h at 378C
under agitation. The digested tissue and cell suspension so-
lution was centrifuged at 200 g for 7min and the supernatant
discarded. The cell pellet was washed with PBS and centri-
fuged again under the same conditions. Cells were again
centrifuged, the supernatant removed, and resuspended in
expansion medium consisting of Dulbecco’s modified Eagle’s
medium (Sigma-Aldrich, MO, USA), containing 10mM [4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid] (HEPES)
buffer pH 7.4, 10,000 units=mL penicillin=10,000mg=mL
streptomycin, 20mM L-alanyl glutamine, 1 minimum es-
sential medium (MEM) nonessential amino acids, and 10%
(v=v) fetal bovine serum (Biochrom, Berlin, Germany; heat
inactivated), supplemented with 10 ng=mL basic fibroblast
growth factor (PeproTech, London, United Kingdom). Hu-
man articular chondrocytes were plated onto tissue culture
flasks and incubated at 378C in a humidified atmosphere of
5% CO2 in air for expansion.
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Encapsulation of human articular chondrocytes
in gellan gum hydrogels and in vitro culturing
Human articular chondrocytes were expanded and encap-
sulated at passage 1 in gellan gum hydrogels using the fol-
lowing procedure. Gellan gumpowderwasmixedwith sterile
distilled water under constant stirring at room temperature to
obtain a final concentration of 1% (w=v). The solution was
progressively heated to 908C and kept at this temperature for
20–30min. A sterile CaCl2 solutionwas added to obtain a final
concentration of 0.03% (w=v). The temperature was progres-
sively decreased to 428C and stabilized at this value for pos-
terior use always under constant stirring. Human articular
chondrocytes were detached by trypsinization, mixed with
expansion medium, and centrifuged at 200 g for 7min. The
supernatant was removed, and the cells were resuspended in
warm sterile PBS solution, counted using an hemocytometer,
and finally centrifuged at 200 g for 7min. The supernatant was
discarded and the cells pellet kept at the bottom of the falcon
tube. The gellan gum 1% (w=v) with CaCl2 0.03% (w=v) so-
lution was added to the pellet of cells and the mixture re-
suspended for complete homogenization of the cellswithin the
matrix. Gellan gum discs containing 8106 cells=mL human
articular chondrocytes were produced by casting this mixture
into sterile cylindrical polystyrene moulds, allowing it to rest
at room temperature for 1–2min to form a solid gel. Discs of Ø
6 0.015.5 0.46mm height were cut using a borer. The
discswere cultured in the expansionmedium for 7 dayswhich
was afterward replacedbydifferentiationmedium for 49days.
The differentiation medium was prepared by replacing the
basic fibroblast growth factor in the expansion medium with
insulin (1mg=mL) and ascorbic acid (50mg=mL) (Sigma-
Aldrich). The culture medium was changed every 3–4 days.
Cell viability: Calcein AM staining
The viability of chondrocytes after 14 days of culture was
assessed using calcein AM staining. Calcein AM (C3099;
Invitrogen Corporation, Carlsbad, CA) assay is a fluores-
cence-based method for assessing cell viability and cyto-
toxicity in which the reagent is retained in cells that have an
intact cell membrane. Briefly, a calcein AM solution of
1=1000 was prepared in culture medium. After the end of
each time point, one disc of gellan gum with encapsulated
human articular chondrocytes was collected from the cul-
turing plates and incubated in the calcein AM solution for
15–30min at 378C and afterward washed in sterile PBS. 40,6-
diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, MO,
USA), a fluorescent stain that binds strongly to DNA, was
used for counterstaining. The samples were observed under
fluorescent microscopy (Zeiss HAL 100=HBO 100; Axiocam
MRc5, Oberkochen, Germany).
Histology (hematoxylin–eosin, Alcian blue, Safranin-O)
Histological analysis was performed with hematoxylin–
eosin (H&E), Alcian blue, and Safranin-O staining on 4 mm
thickness sections of the cell-scaffold constructs collected at
different periods of culture. The samples were fixed in glu-
taraldehyde 2.5% (v=v), for 30–40min at 48C and washed in
PBS. Histological processing was performed using Tecnhovit
7100 (Heraeus Kulzer, Hanau, Germany) following the
commercial procedure. Sections were cut using a microtome
Leica RM2155 (Leica Microsystems, Nusslock, Germany).
H&E staining was performed using automatic processor
(Leica Auto Stainer XL) according to the in-house method-
ology (Leica TP1020-1; Leica MicroSystems). Histological
staining with Alcian blue and Safranin-O was performed
using standard histological methods. The slides were after-
ward washed three times in distilled water, quickly dehy-
drated through 95% and 100% ethanol, and then cleared in
Histoclear (National Diagnostics, Atlanta, GA) andmounted
using Microscopy Entellan (Merck, Rahway, NJ) for obser-
vation.
Real-time polymerase chain reaction
(Sox9, collagen type I, collagen type II, aggrecan)
Samples were collected at defined time periods, quickly
frozen in liquid nitrogen, and stored at 808C until the
analysis was performed. RNA was extracted using TRIzol
(Invitrogen Corporation) according to the provided technical
datasheet. Briefly, three samples of each condition were
grinded and mechanically homogenized with a mortar and
pestle in TRIzol reagent, each condition being performed in
duplicate. Afterward, chloroformwas added and the samples
centrifuged to establish a three-phase composition in the tube.
The aqueous phasewas collected and put in a new tubewhere
isopropanol was added. The samples were centrifuged,
the supernatant discarded and the pellet washed with 75%
ethanol. After a final centrifugation the samples were allowed
to air dry, and suspended in ultrapure water for posterior
analysis. The amount of isolated RNA and A260=280 ratio
was determined using Nanodrop ND-1000 Spectrophoto-
meter (NanoDrop Technologies,Wilmington, DE). After these
determinations, 1mg of RNA of each sample was reverse
transcribed into cDNA using the IScript cDNA synthesis kit
(Bio-Rad Laboratories, Hercules, CA) in a MJ Mini Personal
Thermal Cycler (Bio-Rad Laboratories). Cartilage-related
markers were chosen to evaluate the chondrogenic phenotype
of the cultured systems. These included Sox9, collagen type I,
collagen type II, and aggrecan, using GAPDH as the house-
keeping gene for normalization. The expression of each gene
was normalized to the GAPDH value in that sample. The
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relative gene expression quantification was performed using
the 2DDCt (Livak) method,34 considering that
2DDCt¼normalized expression ratio
All the primer sequences were generated using Primer3
software35 and acquired from MWG Biotech (Ebersberg,
Germany). More details can be found in Table 1. Real-time
polymerase chain reaction (PCR) was performed using an MJ
Mini Personal Thermal Cycler (Bio-Rad Laboratories, CA,
USA) machine and SYBR Green IQ Supermix (Bio-Rad
Laboratories, CA, USA) to detect amplification variations. The
analysis of the results was performed with MJ Opticon
Monitor 3.1 software (Bio-Rad Laboratories).
Subcutaneous implantation
in mice—histology and DMA
Gellan gum discs were prepared under sterile conditions
following a methodology previously described.25 Gellan gum
1% (w=v) (Ø 6 0.01mm5.5 0.46mm height) discs were
subcutaneously implanted in the dorsal part of the Balb=c
mice (2–3 months with an average weight of 20 g) during
periods of up to 21 days. Six female mice were used (two for
each period of implantation). Each animal was anaesthetized
with a mixture of 5:1 Imalgene 1000 (Merial, Toulouse,
France) and Domitor (Orion Corporation, Espoo, Finland)
(1.25mg per mouse and 25 mg per mouse, respectively) pre-
pared in physiological serum. Under surgical sterile condi-
tions, two medial and ventral incisions (approximately
0.7 cm) containing the subcutis and the panniculus carnosus
(skin smooth muscle) were performed in the dorsum of the
mice. Craniolateral oriented pockets (two per incision) were
subcutaneously created by blunt dissection. Into these pock-
ets, the gellan gum discs were inserted (four discs per animal),
and the panniculus carnosus and the skin were carefully su-
tured. The animals were kept with food and water ad libitum
during all the time of implantation. After predetermined time
periods, each test animal was sacrificed, and the implanted
scaffolds and respective surrounding tissue were explanted
from each animal. These were subjected to macroscopic ob-
servation and processed for histological analysis to evaluate
the induced inflammatory response and integration into the
host tissue. Briefly, the explanted samples were fixed with
formalin solution, dehydrated through ethanol solutions, and
embedded in paraffin. Sections with 4 mm thickness of the
gellan gum structure and surrounding tissue interface were
stained with H&E using automatic coloring equipment, as
previously described in the ‘‘Histology (hematoxylin–eosin,
Alcian blue, Safranin-O Section)’’ section. DMA was also
performed using the procedure previously described in the
‘‘Dynamic mechanical analysis’’ section.
Results
Rheological studies
Rheological measurements were performed mainly to
determine the temperature range at which the sol–gel tran-
sition occurred and the time-scale for gelling as these are
important parameters to look into when the material is ex-
pected to be applied as an injectable system and as a cell
encapsulating agent. The sol–gel transition temperature was
observed around 398C (39.4 0.168C) (Fig. 1). This enables
the solution to be injected into the organism and gelate at the
defect site once it stabilizes at the body temperature. More-
over, the low viscosity of the solution before gelation allows
cells to be efficiently mixed and homogeneously dispersed
within the carrier before the application. Regarding the
time-scale for gelling, it is possible to observe from the graph
in Figure 2 that it is approximately 20 s. The results obtained
for both temperature and time of gelation are critical to dem-
onstrate the concept of using gellan gum hydrogels as inject-
able systems for minimally invasive surgical procedures
in vivo. A gellan gum solution can be kept above the sol–gel
transition maintaining a low viscosity that enables cells or
bioactive agents of interest to be homogeneously dispersed.
Upon lowering the temperature, the gel forms entrapping
the cells in its matrix in a rather efficient way.
DMA
The viscoelastic characterization of the gellan gum hy-
drogels was performed using DMA. This technique also
gives important information regarding the mechanical per-
formance that these hydrogels may have once implanted
Table 1. Primers Used for Real-Time Polymerase Chain Reaction Evaluation
of Human Articular Chondrocytes Gene Expression
Gene Accession number Left primer Right primer
Sox9 NM_000346 TTGAGCCTTAAAACGGTGCT CTGGTGTTCTGAGAGGCACA
Collagen type I NM_000089 CTGCAAGAACAGCATTGCAT GGCGTGATGGCTTATTTGTT
Collagen type II NM_001844 TCACGTACACTGCCCTGAAG TGCAACGGATTGTGTTGTTT
Aggrecan NM_001135 ACAGCTGGGGACATTAGTGG GTGGAATGCAGAGGTGGTTT
GAPDH NM_002046 GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG
FIG. 1. Rheological measurements of gellan gum solutions
showing the relation temperature–viscosity and time–
viscosity. The sol–gel transition is noticeable by the change in
viscosity present in the graph around 398C with an extent of
time for gelation of approximately 20 s.
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in vivo. Gellan gum hydrogels were analyzed in the wet state
throughout a physiological relevant frequency range. Storage
(elastic) and loss (viscous) components of the complex mod-
ulus were determined and are shown in Figure 2. The storage
modulus (E0) is about one order of magnitude higher than
the loss modulus (E0 0) which clearly reveals the elastic nature
of these gels. It also possesses some damping capability that
may be useful to dissipate cyclic mechanical energy that is
imposed in an implantation scenario. Although some in-
crease in E0 is observed for increasing frequencies, the elastic
properties of the hydrogel biomaterial, as compared with the
viscous component, are quite stable. An increase in E@ is
observed from 0.6 to 10Hz, suggesting a higher dissipation
capability of gellan gum hydrogels at higher frequencies. At
a frequency of 1Hz, the compression modulus of the gels
was estimated to be of 78.6 2.3 kPa. In fact, although this
value does not mimic the mechanical properties found in
human articular cartilage,36 it is higher or within the range of
values found for other hydrogels used in similar cartilage
regenerative approaches.8,37
Cell viability and histological analysis
Calcein AM coupled with DAPI fluorescence staining was
conducted to confirm the chondrocyte viability. Calcein AM
penetrates the cell membrane of living cells, being subse-
quently hydrolyzed to a cell membrane–impermeable green
fluorescent calcein by esterases present in viable cells. DAPI
is a fluorescent stain that binds strongly to DNA. By cou-
pling these two agents, viable cells are presented with green
cytoplasm and blue nuclei. Results from samples collected
after 14 days of culture are presented on Figure 3 showing
viable human chondrocytes inside the hydrogels. The ma-
jority of the cells were positive for calcein and DAPI, which
indicates a dominance of viable cells. These results show that
both the gellan gum hydrogel is not cytotoxic and that the
temperature cycle used to promote the sol–gel transition
does not affect the cell viability.
Histological analysis of samples taken after 56 days of
culture was performed using H&E for regular morphological
cellular analysis, Alcian blue, and Safranin-O that are
commonly used for staining ECM proteoglycans (glycos-
aminoglycans). H&E-stained slides (Fig. 4A, B) show an
homogeneous chondrocyte distribution throughout the gel-
lan gum hydrogel matrix. Representative images of the de-
position of proteoglycans (glycosaminoglycans) within the
gellan gum matrix, commonly found in native articular
cartilage ECM, can be found in Figure 4C and D. A positive
staining in some pericellular areas of newly formed cell
clusters was observed. An improvement in the nature of the
staining that evolved from a more orthochromatic in the
initial periods of culture (data not shown) to a more pro-
nounced metachromatic staining in the latter periods was
also noticed. This effect was more evident in the regions
where cell clusters formed in comparison to individual
chondrocytes.
Real-time PCR (Sox9, collagen type I,
collagen type II, aggrecan)
Real-time PCR is frequently used to amplify and simul-
taneously quantify a specific sequence in a DNA sample.
This technique was used to assess the expression profile of
different molecules associated with hyaline cartilage ECM
and thereby evaluate the nature and type of matrix that is
being formed. Quantitative data may be obtained on gene
expression and variations that are occurring (upregulation or
downregulation) in comparison to a housekeeping gene.
Sox9, collagens type I and II, and aggrecan are common ECM
constituents, and their expression pattern from 14 to 56 days
of culture was assessed (Fig. 5). GAPDH was chosen as the
reference housekeeping gene since most of the studies pre-
sented on chondrocytes gene expression use this standard
and therefore the results can be analyzed in a comparative
way. The cycle threshold (Ct) value for each sample was
determined only when the exponential phase of amplifica-
tion was reached. In each sample, the Ct value was nor-
malized to the Ct value of the reference gene (GAPDH).
Collagen type II and aggrecan are considered to be the two
FIG. 2. Mechanical properties evaluation of gellan gum
discs using dynamic mechanical analysis. The tests were
performed in intervals of 0.1–15Hz in hydrated samples.
FIG. 3. Calcein AM=40,6-diamidino-2-phenylindole viabil-
ity staining of human articular chondrocytes encapsulated in
gellan gum hydrogels at 14 days of culture. Color images
available online at www.liebertonline.com=ten.
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major and most important constituents of hyaline cartilage
ECM since the functionality of this tissue relies mostly on the
presence of these components. Both collagen type II and
aggrecan experienced a significant increase of approximately
400-fold and 35-fold, respectively, from 14 to 56 days of
culture in the gellan gum with encapsulated human chon-
drocytes hybrid systems. Collagen type I was not detected
after 56 days and Sox9 was downregulated to values close to
zero from 14 to 56 days.
In vivo tests: Histology, mechanical analysis,
and weight measurements
The initial response of a living organism to any kind of
implanted biomaterial is absolutely necessary before pro-
ceeding to further tissue engineering studies. For this, the
subcutaneous implantation of a biomaterial and the subse-
quent evaluation of the extent of the provoked inflammatory
response is a common first screening methodology. As a way
to confirm the adequacy of the developed hydrogels to be
put through further screening, gellan gum discs were sub-
cutaneously implanted in the back of Balb=c mice for periods
of up to 21 days. Upon explantation, no evident macroscopic
changes of the discs and surrounding tissues were observed
after this period and the discs maintained its structural
FIG. 4. Histological analysis of sections of gellan gum with human articular chondrocytes after culturing. Hematoxylin–
eosin (A, B—after 2 and 56 days of culture, respectively) was used for general cell morphology and distribution, whereas
Alcian blue (C) and Safranin-O (D) were performed for proteoglycans (glycosaminoglycans) detection. Color images avail-
able online at www.liebertonline.com=ten.
FIG. 5. Graphical representation of the real-time semi-
quantitative polymerase chain reaction analysis for collagen
type I, collagen type II, aggrecan, and Sox9 based on the
mRNA produced by the encapsulated human articular
chondrocytes after 14 and 56 days of culture. Statistical
analysis through the various time points (p> 0.05) was per-
formed using a two-sample t-test assuming unequal var-
iances for n¼ 3, a¼ 0.05. Statistically significant differences
are marked with an asterisk (*).
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integrity. Histological analysis of the explanted samples,
stained with H&E, showed good integration within the
surrounding host tissue. In terms of inflammatory response–
associated cells, the normal presence of neutrophils was
observed at 7 days of implantation (Fig. 6A, B). This cell
population revealed a progressive decrease along the
implantation time, almost inexistent at 14 days (Fig. 6C, D).
Additionally, a thin and residual fibrotic capsule (Fig. 6E, F)
and the infiltration of some phagocytic cells (Fig. 6F, arrow)
were evident by the end of 21 days. DMA performed on the
hydrogel samples at different periods of explantation re-
vealed no statistically significant differences between the
samples, although a slight decrease tendency in the com-
pressive modulus was noticed (Fig. 7). In terms of weight
measurements, which can be an indicator of biodegradation
of gellan gum hydrogels, a statistical difference was ob-
served after 21 days of implantation. Although the weights
of the samples at different time points did not present rele-
vant alterations, a statistically significant decrease was no-
ticed after 21 days when compared with nonimplanted
gellan gum gel discs and gel discs with 14 days of implan-
tation (Fig. 8).
FIG. 7. Storage and loss modulus at 1Hz obtained from
compression dynamic mechanical tests of gellan gum discs
after subcutaneous implantation in Balb=c mice. Statistical
analysis was performed using a two-sample t-test assuming
unequal variances for n¼ 5, a¼ 0.05 and revealed no differ-
ence through the various time points ( p> 0.05).
FIG. 8. Weight measurements of gellan gum discs after
subcutaneous implantation in Balb=c mice. Statistical analy-
sis revealed a significant difference (*) in gellan discs im-
planted for 21 days when compared with no implant and 14
days of implantation. Statistical analysis through the various
time points ( p> 0.05) was performed using a two-sample
t-test assuming unequal variances for n¼ 5, a¼ 0.05.
FIG. 6. Histological analysis showing two different magnifications of sections of gellan gum after 7 (A, B), 14 (C, D), and
21 (E, F) days of implantation. The images evidenced a good integration with the surrounding tissue and the progressive
reduction of the fibrotic capsule that was almost unnoticed after 21 days. The arrow (F) indicates the infiltration of phagocytic
cells. Color images available online at www.liebertonline.com=ten.
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Discussion
The use of hydrogels in cartilage regeneration is consid-
ered to be a promising strategy due to some intrinsic features
that they frequently exhibit. Most of them can be applied as
minimally invasive systems that are able to deliver cells
and=or bioactive agents of interest in situ and to keep them at
the implantation site. The processing under mild conditions
coupled to the use of nonharsh reagents is another positive
aspect. In addition, the gelation in situ enables the formed
hydrogel to quickly set its volume and easily adapt to the
shape of the defect site, establishing an efficient integration
with the host tissue.38 Gellan gum is a new biomaterial
proposed for cartilage regeneration that exhibits those fea-
tures. It can be prepared by simple methods using nonag-
gressive reagents and can be combined with cells or bioactive
agents of interest at the body temperature and physiological
pH. It can be injected under a minimally invasive surgical
intervention and gelate upon temperature stabilization at
body temperature giving rise to an efficient defect filling and
cell entrapment system. Another potentially interesting as-
pect is the structural unit of gellan gum that includes glu-
curonic acid in its composition.19 This monosaccharide
residue possesses a functional carboxylic group that may be
modified to confer improved functionalities to this bioma-
terial. One final aspect is the fact that this biomaterial is al-
ready used in humans in ophthalmic applications,39 which
may clearly enable a fast approval by the regulatory bodies.
In this work, gellan gum hydrogels were tested for their
ability to be used as injectable systems using simple methods
in cartilage repair applications, which may be useful in the
future in minimally invasive approaches. The injectability of
this biomaterial was analyzed and confirmed by rheological
measurements. Cone-plate rheology was used to determine
the temperature range and time duration of the sol–gel
transition in gellan gum hydrogels. The gellan gum solution
revealed a consistent increase in viscosity around 408C that
stabilized at approximately 398C, being the temperature at
which the gelation process is finalized. This analysis also
provided data on the time during which this process oc-
curred which was shown to be of approximately 20 s. The
interpretation of both these parameters demonstrates the
potential of these hydrogels to be used as minimally inva-
sive injectable systems that are able to deliver and encap-
sulate cells and=or bioactive agents to a defect site in the
human body. In addition, the injectability of gellan gum
hydrogels is good since their viscosity before the onset of
gelation is low, enabling the overall mixing and application
of the gel to be easily conducted. Mechanical properties
tested using DMA retrieved a wet state compression mod-
ulus of approximately 80 kPa at a frequency of 1Hz analyzed
in the wet state using a physiologically relevant frequency
range. The storage modulus (E0) is about one order of mag-
nitude higher than the loss modulus (E0 0) which indicates an
elastic nature of gellan gum. Some damping capability was
noticed when analyzing tan d results, which may be con-
sidered an advantage for dissipating some cyclic mechanical
energy that is generated in vivo. This value is fairly good
when compared to other hydrogels frequently described in
the literature for cartilage regenerative approaches.8,37
Nonetheless, human cartilage exhibits higher compressive
modulus of approximately one order of magnitude.36 This
difference is expected to be compensated by ECM deposition
during the formation of a cartilaginous structure.8 In vitro
tests showed that chondrocytes were viable and homoge-
neously distributed inside the hydrogels as observed under
fluorescence microscopy using calcein AM combined with
DAPI and H&E staining. The chondrocytes’ typical round-
shaped morphology was confirmed at both initial and long-
term culture periods. Cell dispersion throughout the gellan
gum matrix was quite homogeneous and the cells main-
tained normal morphological features and active division to
some extent. Using the calcein AM-DAPI staining it was
possible to observe that the chondrocytes are viable inside
the matrix, although cell division state may somehow be
limited due to the physical restrictions of the hydrogel net-
work which is a typical feature in similar systems.40 None-
theless, it may be that the carbohydrate nature of gellan gum,
which contains high glucose content, can be used as a source
of energy by the cells, thereby progressively giving rise to
spaces within the hydrogel matrix and the consequent
chondrocyte proliferation. Ongoing work performed by our
group on the subcutaneous implantation of gellan gum discs
through extensive periods has gathered consistent informa-
tion that corroborates this hypothesis. Other mechanical
events associated with cell proliferation may include the
formation of microcracks and the propagation of fracture
creating additional spaces for cell growth. Besides cells’
viability and distribution, the formation of an adequate ECM
is of utmost importance to the performance of the tissue-
engineered construct. Active collagen type II and aggrecan
deposition contributes to the formation of a functional hya-
line-like cartilage-engineered tissue. These are in fact the
two major ECM molecules responsible for the articular car-
tilage mechanical properties; collagen type II confers tensile
strength, and aggrecan is responsible for the compressive
resistance.41 Alcian blue and Safranin-O performed after 56
days of culturing on sections of gellan gum with encapsu-
lated human articular chondrocytes evidenced glycosami-
noglycans deposition in the pericellular regions of most cell
clusters. Real-time PCR analysis for Sox9, collagen I, collagen
II, and aggrecan strengthened these findings confirming the
increased levels of expression of transcripts from collagen
type II and aggrecan from 14 to 56 days. Collagen type II was
upregulated approximately 400-fold and aggrecan approxi-
mately 35-fold; no statistically significant variation in Sox9
was encountered and no collagen type I was detected. Such
results clearly show that human articular chondrocytes
encapsulated in gellan gum hydrogels were able to deposit
a hyaline-like ECM, therefore contributing to the formation
of a functional tissue-engineered construct. However, the
low expression of Sox9 seems to diverge from this pattern
since this factor is apparently associated with the chon-
drocyte phenotype maintenance and collagen type II ex-
pression, although this is not consensual.42,43 Chondrocytes
from osteoarthritis cartilage present low levels of Sox9,43 and
the cell source may be a possible explanation for this oc-
currence. Also, the dedifferentiation process occurring dur-
ing in vitro expansion44 or the existence of some associated
hypertrophy of the chondrocytic cells may be occurring.45
The following step in this study was to evaluate the re-
sponse of a host to a first contact with this biomaterial, which
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to our knowledge is for the first time report in this work.
Gellan gum discs were subcutaneously implanted in the back
of Balb=c mice, and histological analysis was conducted to
assess the inflammatory processes associated with the im-
plantation, as well as the integration into the host tissue. A
negligent, thin, and residual fibrotic capsule was observed
with no evident polymorphonuclear and mononuclear cells
present, as well as a good integration with the involving
tissues. It should be mentioned that some phagocytic cell
infiltration (Fig. 6F, arrow) into the hydrogel matrix was
observed after 21 days, indicating that this might be a
probable scenario in further in vivo studies. One might
speculate that such an event will enable gellan gum with
encapsulated cell systems to efficiently integrate with the
host tissues and establish a functional transition zone at the
interface area, although this must be shown in further
studies.
DMA performed on the explants after the defined time
periods revealed no statistically significant differences
among the various samples. Weight measurements showed
that although no relevant alterations were detected, a sig-
nificant decrease was noticed after 21 days. This may cor-
relate with some cell infiltration into the gellan gum
hydrogel matrix and possible resorption, as observed in
the histological analysis. In an in vivo scenario where the
gellan gum carries encapsulated cells intended to form a
tissue, the tendency may be the deposition of a cartilage-like
ECM along with the possible degradation of the hydrogel.
Further studies on this respect will be conducted to under-
stand how gellan gum will degrade or will be replaced at the
implantation site by the newly formed tissue. As a summary,
this work demonstrates the potential of gellan gum hydro-
gels to be used as injectable systems in minimally invasive
surgical procedures for cartilage regeneration. The properties
of this biomaterial were characterized and shown to be
compatible with the application envisaged. The in vitro
studies with clinically relevant cells showed successful hu-
man articular chondrocyte viability and ECM formation,
culminating with the in vivo reaction evaluation upon im-
plantation of the gels in an ectopic site. The overall data
analysis shows that this injectable system has all the re-
quirements to be used for cartilage tissue engineering and its
potential should continue to be assessed by further in vivo
studies.
Conclusions
Gellan gum hydrogels were originally proposed and used
in the herein presented studies as injectable systems for cell
delivery and support, aimed at cartilage regeneration, using
simple nonharsh processing methodologies. Gellan gum
ability to be applied as a minimally invasive system upon
injection and in situ gelation was supported by rheological
measurements. The gels exhibit a low viscosity between 428–
418C enabling an efficient and homogeneous mixing of the
cells, that can afterwards be injected forming a stable gel with
entrapped cells when reaching the body temperature. Gela-
tion occurs around 398C in about 20 s. The evaluation of the
mechanical properties of the hydrogels showed that these are
within the normal range of other hydrogels used in these
applications and should be able to adapt to the cartilage en-
vironment. In vitro tests performed with human articular
chondrocytes encapsulated in gellan gum hydrogels revealed
that the cells remained viable and produced hyaline-like ECM
as observed by the significant increase of collagen type II
and aggrecan after 56 days of culture. Subcutaneous im-
plantation of these materials in the back of mice revealed
highly satisfactory results since the histology evidenced in-
tegration of the gels within the host tissue with no persistent
inflammatory response. The DMA showed that the gels
maintained their mechanical stability, and weight measure-
ments by the end of the experiments reinforced these obser-
vations. Taking together all these data, it can be concluded
that gellan gum hydrogels are adequate for injectable appli-
cations and in situ cell delivery in cartilage regeneration
approaches. This new biomaterial has generated interesting
and promising results that justify its use in further in vivo
studies highly benefiting from their ease of processing per-
formed under nonharmful conditions to the cells with the
ability to be injected at the defect site in a minimally invasive
manner. Its ability to be used as an injectable system using
the described processing methodologies and the prelimi-
nary in vivo response performed by the subcutaneous im-
plantation in mice are the two major innovations presented in
this work.
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